Look out for the first interim results of the OASIS II randomised trial at #ASH24 Fixed duration 1L antiCD20-IBR vs AntiCD20-IBR-VEN #MCL #ASH24

Not long to go now! Quite the line up 👀 LymphomaAction #LymphomaManagement

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia buff.ly/3MieaKm Jaimal Kothari Toby Eyre Kush Ediri

Ready, AIM, stop: ibrutinib plus venetoclax in MCL ow.ly/QKlL50T4f1k #clinicaltrialsandobservations

#Hematology BTKi is the preferable second-line approach in patients with BTKi-naïve mantle-cell #lymphoma, regardless the time of relapse #lymsm

COVID-19 Vaccination During Therapy in Relation to COVID-19 Death in CLL ashpublications.org/bloodadvances/…

BTKi is better: a lesson learned? ashpublications.org/blood/article/…

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…

Ibrutinib plus rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL: A phase II ALLG study ashpublications.org/bloodadvances/…

Overall, chemoimmunotherapies as second-line treatment are discouraged in the era of chimeric antigen receptor T-cell therapies. ow.ly/NJMI50TeJr7 #lymphoidneoplasia

BTKi is better: a lesson learned? ow.ly/mtul50TeJH2 #lymphoidneoplasia

A fresh look at covalent BTK inhibitor resistance ashpublications.org/blood/article/…

Many congratulations to Ross Salvaris who has written a very nice review on the fascinating, controversial and still understudied nodular LP Hodgkin Lymphoma. 👏👏

It's a wrap! #LymphomaManagement 2024 is over, thank you to everyone who attended and made it such a fantastic event. We are already excited about next year so if you are a healthcare professional working in #Lymphoma, stay tuned! #LymSM Oxford Centre for Haematology Toby Eyre Graham Collins

MCL BR-based induction and R-based maintenance gave 88% overall response rate, 91% measurable residual disease–negative and median PFS 6.9 years. ow.ly/3eA850TgB1C #lymphoidneoplasia #clinicaltrialsandobservations

LymphomaAction Oxford Centre for Haematology Toby Eyre Many thanks thanks indeed to all those who made this happen. An incredible faculty, attendees, our sponsors and especially to Rona and others LymphomaAction who support this every year - incredible job, well done.

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial - The Lancet Oncology thelancet.com/journals/lanon…

British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

AutoSCT vs alloSCT in CR1 for PTCL Long term f/up of AATT RCT Journal of Clinical Oncology 7 yr EFS: allo 38% v auto 34% 7 yr OS: allo 55% v auto 61% 15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23% ascopubs.org/doi/10.1200/JC… Allo the goal in fit PTCL